Drug Trial Radar · NCT04146285
A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
Last checked: Nov 19, 2026Latest source record: Jul 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Sep 1, 2020
Primary completion
Mar 13, 2023
Study completion Dec 25, 2023
Sponsor
- Lead sponsor
- Bio-Thera SolutionsIndustry
- Sponsor type
- Industry
- First posted
- Oct 31, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a phase I clinical study of the safety, tolerability, and pharmacokinetics of BAT4406F injection in patients with neuromyelitis optica spectrum disorders.
Conditions
- Neuromyelitis Optica Spectrum Disorders
Interventions
BAT4406FDrug
Open-label dose escalation starting from 20mg. Route of administration: intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity(DLT)Time frame: 4weeks
- Maximum tolerated dosed (MTD)Time frame: up to 6 months
- Area under the curve (AUC)Time frame: up to 6 months
- Maximum serum drug concentration (Cmax)Time frame: up to 6 months
- Half-life period(t1/2)Time frame: up to 6 months
- Maximum serum drug time (Tmax)Time frame: up to 6 months
- CD19+ B lymphocyte ratioTime frame: up to 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.